Milosz Wilczynski

Dr. Milosz Wilczynski

Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother’s Memorial Hospital Research Institute, Poland
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JWJacek R Wilczyński
Jacek R Wilczyński
MWMilosz Wilczynski
Milosz Wilczynski
EPEdyta Paradowska
Edyta Paradowska
Ovarian cancer is the most lethal neoplasm of the female genital organs. Despite indisputable progress in the treatment of ovarian cancer, the problems of chemo-resistance and recurrent disease are the main obstacles for successful therapy. One of the main reasons for this is the presence of a specific cell population of cancer stem cells. The aim of this review is to show the most contemporary knowledge concerning the biology of ovarian cancer stem cells (OCSCs) and their impact on chemo-resistance and prognosis in ovarian cancer patients, as well as to present the treatment options targeted exclusively on the OCSCs. The review presents data concerning the role of cancer stem cells in general and then concentrates on OCSCs. The surface and intracellular OCSCs markers and their meaning both for cancer biology and clinical prognosis, signaling pathways specifically activated in OCSCs, the genetic and epigenetic regulation of OCSCs function including the recent studies on the non-coding RNA regulation, cooperation between OCSCs and the tumor microenvironment (ovarian cancer niche) including very specific environment such as ascites fluid, the role of shear stress, autophagy and metabolic changes for the function of OCSCs, and finally mechanisms of OCSCs escape from immune surveillance, are described and discussed extensively. The possibilities of anti-OCSCs therapy both in experimental settings and in clinical trials are presented, including the recent II phase clinical trials and immunotherapy. OCSCs are a unique population of cancer cells showing a great plasticity, self-renewal potential and resistance against anti-cancer treatment. They are responsible for the progression and recurrence of the tumor. Several completed and ongoing clinical trials have tested different anti-OCSCs drugs which, however, have shown unsatisfactory efficacy in most cases. We propose a novel approach to ovarian cancer diagnosis and therapy.

27 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EPEdyta Paradowska
Edyta Paradowska
AJAgnieszka Jabłońska
Agnieszka Jabłońska
MSMirosława Studzińska
Mirosława Studzińska
MWMilosz Wilczynski
Milosz Wilczynski
JWJacek R. Wilczyński
Jacek R. Wilczyński
Viral and bacterial infections are detected in epithelial ovarian cancer (EOC) tissues. Since the fallopian tubes are often affected by pelvic inflammatory disease (PID) and the majority of serous EOCs appear to originate from dysplastic lesions in the distal tube, it is relevant to consider the potential role that infectious agents may play in ovarian carcinogenesis. We sought to analyze the prevalence of human papillomavirus (HPV) and cytomegalovirus (CMV) in EOC tissue and fallopian tube specimens obtained at tumor resection. Ovarian cancer and fallopian tube tissue samples obtained from patients with EOC were analyzed by both qualitative and quantitative PCR to detect and quantify viral DNA. The presence of CMV and HPV DNA was detected in 70% and 74% cancerous ovarian tissues, respectively, and was significantly higher in EOC than in benign tumor cases (P ≤ 0.01). CMV or HPV infection was observed also in the fallopian tube samples. Infection with HPV16 was determined in 70% of EOC cases. Almost two thirds of EOC patients demonstrated coinfection with CMV and HPV in the pathological samples. The results revealed that the presence of CMV and HPV in EOC samples is common. CMV and HPV infections can be potential risks for EOC development.

13 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MWMilosz Wilczynski
Milosz Wilczynski
JDJustyna Danielska
Justyna Danielska
MDMonika Dzieniecka
Monika Dzieniecka
BSBozena Szymanska
Bozena Szymanska
MWMichal Wojciechowski
Michal Wojciechowski
AMAndrzej Malinowski
Andrzej Malinowski
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to patients’ clinical and histopathological features, such as: survival rate, recurrence rate, staging, myometrial invasion, grading and lymph nodes involvement. Higher levels of miRNA-205 expression were observed in tumours with less than half of myometrial invasion and non-advanced cancers. Kaplan-Maier analysis revealed that higher levels of miRNA-205 were associated with better overall survival (p = 0,034). These results indicate potential clinical utility of miRNA-205 as a prognostic marker.

23 June 2017 in Oncology Letters
Verified
Journal Article
Open access
PDF file
MWMilosz Wilczynski
Milosz Wilczynski
EŻEwelina Żytko
Ewelina Żytko
BSBozena Szymanska
Bozena Szymanska
MDMonika Dzieniecka
Monika Dzieniecka
Marek NowakMarek Nowak
Marek Nowak
JWJacek R. Wilczyński
Jacek R. Wilczyński
The aim of the present retrospective study was to compare microRNA (miR)-146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR-146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR-146a was evaluated in formalin-fixed, paraffin-embedded samples. miR-146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR-146a expression in primary tumors and serum levels of cancer antigen 125 (R=−0.37; P=0.03) and Risk of Malignancy Algorithm index (R=−0.79; P=0.0007). Overall survival positively correlated with miR-146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR-146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006). In conclusion, miR-146a may be a prognostic marker for serous ovarian cancer.

21 January 2018 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
MWMilosz Wilczynski
Milosz Wilczynski
JDJustyna Danielska
Justyna Danielska
DDDaria Domanska‐Senderowska
Daria Domanska‐Senderowska
MDMonika Dzieniecka
Monika Dzieniecka
BSBozena Szymanska
Bozena Szymanska
AMAndrzej Malinowski
Andrzej Malinowski
Introduction: MicroRNAs (miRNAs) are regulators of gene expression, which play an important role in many critical cellular processes including apoptosis, proliferation and cell differentiation. Aberrant miRNA expression has been reported in a variety of human malignancies. Therefore, miRNAs may be potentially used as cancer biomarkers. miRNA‐200c, which is a member of the miRNA‐200 family, might play an essential role in tumor progression. The purpose of this study was to evaluate the prognostic and clinical significance of miRNA‐200c in women with endometrioid endometrial cancer.Material and methods: Total RNA extraction from 90 archival formalin‐fixed paraffin‐embedded tissue samples of endometri‐oid endometrial cancer and 10 normal endometrium samples was performed. After cDNA synthesis, real‐time polymerase chain reaction was conducted and relative expression of miRNA‐200c was assessed. Then, miRNA‐200c expression levels were evaluated with regard to clinicopathological characteristics.Results: The expression levels of miRNA‐200c were significantly increased in endometrioid endometrial cancer samples. Expression of miRNA‐200c maintained at significantly higher levels in the early stage endometrioid endometrial cancer compared with more advanced stages. In the Kaplan–Meier analysis, lower levels of miRNA‐200c expression were associated with inferior survival.Conclusions: Expression levels of miRNA‐200c might be associated with clinicopathological factors and survival in endometrioid endometrial cancer.

5 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
KKKatarzyna Dominika Kania
Katarzyna Dominika Kania
DHDaria Haręża
Daria Haręża
JWJacek R Wilczyński
Jacek R Wilczyński
MWMilosz Wilczynski
Milosz Wilczynski
DJDariusz Jarych
Dariusz Jarych
EPEdyta Paradowska
Edyta Paradowska
Ovarian cancer (OC) is one of the most common cancers threatening women’s lives around the world. Epithelial ovarian tumors represent the most common ovarian neoplasms. Most OC patients are diagnosed at the advanced stage, and there is an urgent need to identify novel biomarkers of the disease. Single-nucleotide polymorphisms (SNPs) in TLR genes may serve as crucial markers of cancer susceptibility. We investigated the frequency of TLR polymorphisms in a group of 200 women, including 70 with OC. Four SNPs, two each in TLR4 (rs4986790 and rs4986791) and TLR9 (rs187084 and rs5743836), were analyzed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP). The digested fragments were separated and identified by multicapillary electrophoresis. The load quantification of human papillomavirus (HPV) types 16/18 was determined using a digital droplet PCR method. We found an increased frequency of heterozygous genotype and minor allele of the TLR4 rs4986790 SNP in women with OC compared with healthy controls, and this result remained highly significant after Bonferroni’s correction for multiple testing (p < 0.0001). No evidence of linkage disequilibrium was found with any of the examined TLR SNPs. The findings suggest that the TLR4 Asp299Gly polymorphism could be a genetic risk factor for the development of OC.